Executive Team

Chief Executive Officer

Andrin Oswald, M.D.

Chief Executive Officer

Andrin serves as CENTOGENE’s Chief Executive Officer – holding extensive experience in the healthcare sector.

Andrin was Director of Life Science Industry Engagement and Partnerships at the Bill & Melinda Gates Foundation, a role he held for four years in which he led the Foundation’s engagement with the industry and supported teams in developing and advancing its Global Health and Development priorities in R&D and delivery technologies. Prior to his role at the Bill & Melinda Gates Foundation, he oversaw business integration at GlaxoSmithKline - working directly with the CEO to advise on business and integration strategy. Before joining GlaxoSmithKline, he spent more than 10 years in a variety of leadership roles at Novartis, including serving as Assistant to the Chairman and CEO of Novartis International AG; Country President for Novartis South Korea; Head of Global Development Franchises and a member of the Executive Committee for Novartis Pharma; and ultimately, CEO/Division Head of Novartis Vaccines & Diagnostics and a member of the Novartis Executive Committee, based in Boston. Andrin began his career in 1999 with McKinsey & Company, where he worked in various roles managing relationships and supporting projects with leading pharmaceutical and diagnostics companies in Europe and the U.S.

Before joining CENTOGENE, Andrin served as the Delegate for COVID-19 Vaccines and Immunotherapies for the Federal Government of Switzerland, helping develop response and procurement strategies while advising the Swiss government on key decisions.

Throughout his career, Andrin has also served on several boards, including the Novartis Foundation for Sustainable Development in Basel, Switzerland; the Global Health Innovation Technology Fund in Tokyo, Japan; and the Global Health Investment Corporation, where he was also a founding member.

Kim Stratton

Kim Stratton

Interim Chief Executive Officer

Kim currently serves as CENTOGENE’s interim Chief Executive Officer, during the temporary medical leave of CEO Andrin Oswald, M.D.

Kim has more than 25 years’ global commercial expertise in the biopharmaceutical space, with significant experience across multiple geographies, including the U.K., U.S., Europe, and emerging markets. Most recently, Kim was CEO of Orphazyme, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases.

Prior to this role, she worked at Shire Pharmaceuticals, where she served as Head International Commercial for Shire’s Specialty and Rare Diseases portfolio. Before Shire, Kim spent nearly 15 years at Novartis in a number of senior management roles, including global product development, commercial, marketing, general manager, and various global corporate functions, including government and external affairs. Kim is on the Board of Recordati S.p.A, Novozymes A/S and Vifor Pharma AG.


Maximilian Schmid, M.D.

Chief Commercial Officer – Diagnostics

Max serves as CENTOGENE’s Chief Commercial Officer Diagnostics. Bringing over two decades of Experience, Max has the overall responsibility ...

... of driving the company’s Diagnostic business strategy and growth. He joins CENTOGENE from Roche Diagnostics, where he most recently served as Global Head of Medical Affairs of its Sequencing Business Unit. Within this role, he was responsible for developing and executing the medical strategy across different countries and disease areas, such as Oncology and Women’s Health. He came to Roche following the acquisition of Silicon Valley startup Ariosa Diagnostics Inc., where after a successful career in academic medicine, he helped build a leading global NIPT business.

Prior to his medical career, Max worked as a Management Consultant for McKinsey & Company – developing and implementing strategies and solutions to overcome complex challenges in the pharmaceutical and biotechnology industry.

Furthermore, he holds a medical degree from the University of Vienna and is board-certified with habilitation in Obstetrics and Gynecology and sub-specialty training in Maternal-Fetal Medicine, as well as certification in Clinical Genetics.

Prof. Peter Bauer,  M.D.

Chief Genomic Officer

Prof. Peter Bauer, M.D., serves as CENTOGENE's Chief Genomic Officer, where he combines an extensive clinical and medical understanding of genetic testing ...

... with an excellent knowledge of the latest scientific developments.

Peter is passionate about turning medical questions into complete and fast analytical processes – ensuring that medically-driven results are brought to clinicians and patients immediately.

He received his board certification in Human Genetics in 2006 and previously headed the Molecular Diagnostic Laboratory at the Institute of Medical Genetics and Applied Genomics at the University Hospital Tübingen. Additionally, he is Vice President of the German Society of Neurogenetics (DGNG). Peter has authored more than 140 publications in Neurogenetics, Oncogenetics, Cardiogenetics, and Sequencing Technology.


Michael Motz, Ph.D.

Chief Commercial Officer - Pharmaceuticals

Michael serves as Chief Commercial Officer, Pharmaceuticals, overseeing the company's Pharma business strategy and growth. He is an entrepreneur and executive with ...

... over 25 years of industry experience and has held positions of increasing responsibility in both biotech and pharmaceutical companies during his career. He concluded several large transactions, licensing (in- and out-), and acquisitions with EU and U.S.-based life science companies, on both the buy side and the sell side. His experiences have also allowed him to gain expert knowledge in drug discovery and development for rare diseases, such as lysosomal storage diseases (LSDs) and certain rare bone disorders.

Michael holds a doctorate in Biochemistry from the Max Planck Institute for Evolutionary Anthropology, obtained under the supervision of renowned human geneticist Prof. Dr. h.c. Svante Pääbo. Before joining CENTOGENE, he was in leadership positions at several pharma and biotech companies, such as LION Bioscience AG, ALTANA Pharma, Sandoz, F. Hoffmann-La Roche AG, and Zealand Pharma. Most recently, Michael was Entrepreneur in Residence at BB Pureos Bioventures in Zurich, Switzerland.

Patrice P. Denèfle, Ph.D.

Chief Scientific Officer

Patrice P. Denèfle serves as CENTOGENE’s Chief Scientific Officer. Within this role, he is responsible for overseeing the company’s scientific activities to deliver on its vision and strategy, ...

... while driving value creation.

Patrice is a seasoned executive and scientific pioneer with over 35 years of experience at pharmaceutical and biotechnology companies in Europe and the U.S. – spearheading translational R&D to deliver breakthrough treatments to patients.  

Prior to joining CENTOGENE, Patrice served as Chief Scientific Officer at 4P-Pharma, where he led the R&D drug repositioning strategy and operations towards potential full clinical demonstration and asset-value transfer to large pharma companies. Over the past three decades, he has held several leadership positions, including as the General Manager of the Roche Institute for Research and Translational Medicine, as well as other senior roles at Sanofi Aventis and Ipsen. Patrice also served as CSO at Genethon, a biotech company dedicated to the development of gene therapy treatments for rare diseases.  

Patrice received his Ph.D. in Molecular Biology and Biotechnology from the Pasteur Institute, Paris, completed his HDR (Habilitation) in Molecular Pharmacology at the University of Lille, graduated as Adjunct University Professor, and taught Biotechnology for 10 years at the University Paris-Descartes. He was also trained as a CEDEP fellow at INSEAD and has co-authored more than 150 scientific papers and patents.

Nathalie Daste

Chief Human Resources Officer

Bringing extensive experience in organization and capability building in the healthcare sector, Nathalie is responsible for further developing the company’s global talent, ...

... fostering company culture, and expanding organizational capabilities to deliver against a purpose-driven growth strategy. Nathalie has a proven track record in successfully supporting the growth and strategy of leading companies in the healthcare sector globally, including at McKinsey & Company and Novartis. Over the past decade, she has spearheaded a number of large-scale efforts in the area of culture change, performance improvement, top team alignment, and talent and organizational development.

Nathalie holds both a master's in Management from ESSEC and an MBA from INSEAD.

René Just

Chief Financial Officer

René Just serves as Chief Financial Officer. Within his role, he is responsible for the development and implementation of value creation strategies, ...

... as well as the planning and execution of financial strategies. René is a seasoned finance executive with over 20 years of industry experience. During his career, René has held positions of increasing responsibility in both listed and private equity owned companies, spanning a range of industries, including Pharma, IT, and Services. Throughout this time, René has gained extensive experience in building and leading efficient finance operations – supporting the development and implementation of value creation strategies, as well as the planning and execution of financing strategies.

René Just holds a Master of Economics from Aarhus University (Denmark). Before joining CENTOGENE, he was the Group CFO at Riemser Pharma Holding, previously owned by the private investment and private equity firm Ardian.

Florian Vogel, Ph.D.

Chief Process Officer

Dr. Florian Vogel currently serves as the Chief Process Officer at CENTOGENE GmbH. Within his role, he holds disciplinary and budget responsibility for ...

... all five Diagnostic wet lab production departments in Rostock, Germany, and the CLIA & CAP lab processing facility in Cambridge, Massachusetts. In addition, he is responsible for the Method & Process Development in Rostock. Before taking on this position, he served as Senior Director Research & Development from 2015-2018 at CENTOGENE.

Florian has extensive experience in product development and streamlining of workflows for genetically based methods enabling the highest quality as well as high throughput testing. Florian has more than 10 years of know-how in molecular genetic assay design and international leadership in various industry sections.

Prior to joining CENTOGENE, he was living in South Korea to set up a local German branch university and labs for chemical- and bioengineering as Head of the White Biotechnology department, including lab build out and starting industry collaborations.

Florian studied Biology at Friedrich-Alexander-University of Erlangen-Nurnberg and received his doctoral degree in Molecular Biology with summa cum laude.

Volkmar Weckesser, Ph.D.

Chief Information Officer

Volkmar serves as Chief Information Officer. Responsible for heading CENTOGENE's distributed and centralized business operations, he oversees the company's ...

... global development of the IT-based genetic software infrastructure and rare disease-centric Bio/Databank.

Volkmar brings over 20 years of experience in IT, management of large transformation programs, and process optimization. He previously served as CIO of the Gothaer Insurance Enterprise and CEO of the incorporated Gothaer Systems GmbH, where he successfully implemented a new IT-strategy, realigned their IT-architecture, and restructured the project portfolio.

From 2009 to 2013, Volkmar was Director of IT at DekaBank – guiding the modernization of the IT systems and the establishment of new IT governance in close collaboration with all parties involved.

Prior to that, he served as Director of IT/Organization at the HSH Nordbank AG, where he focused on the planning and implementation of the enterprise-wide IT strategy. He also successfully executed the consolidation of the IT systems (post-merger IT integration) at the HSH Nordbank AG.

Volkmar started his career as a Management Consultant for the Mitchell Madison Group and Monitor Company.

He studied Technomathematics at the University of Karlsruhe and holds a doctorate in Mathematics.